Janet Maleski

2.6k total citations · 1 hit paper
26 papers, 2.0k citations indexed

About

Janet Maleski is a scholar working on Oncology, Biological Psychiatry and Molecular Biology. According to data from OpenAlex, Janet Maleski has authored 26 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Biological Psychiatry and 8 papers in Molecular Biology. Recurrent topics in Janet Maleski's work include Tryptophan and brain disorders (12 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Cancer Treatment and Pharmacology (7 papers). Janet Maleski is often cited by papers focused on Tryptophan and brain disorders (12 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Cancer Treatment and Pharmacology (7 papers). Janet Maleski collaborates with scholars based in United States, United Kingdom and Russia. Janet Maleski's co-authors include Thomas F. Gajewski, Omid Hamid, Tara C. Mitchell, Lance Leopold, Yufan Zhao, Tae Min Kim, James Larkin, Matteo S. Carlino, Caroline Robert and Ana Arance and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Janet Maleski

25 papers receiving 2.0k citations

Hit Papers

Epacadostat plus pembroli... 2019 2026 2021 2023 2019 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
    2019 703 citations Georgina V. Long, Reinhard Dummer et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Janet Maleski United States 17 1.3k 836 600 518 332 26 2.0k
De-Sheng Weng China 23 846 0.7× 787 0.9× 104 0.2× 470 0.9× 179 0.5× 33 1.6k
Gengjie Yang United States 13 289 0.2× 182 0.2× 149 0.2× 291 0.6× 99 0.3× 21 814
Agnes Witkiewicz United States 16 552 0.4× 94 0.1× 61 0.1× 459 0.9× 166 0.5× 25 1.1k
Jamaal Rehman United States 8 1.4k 1.1× 478 0.6× 57 0.1× 175 0.3× 758 2.3× 10 1.8k
Dorothee Gramatzki Switzerland 19 335 0.3× 212 0.3× 35 0.1× 444 0.9× 345 1.0× 59 1.4k
Hua Zhong China 19 723 0.6× 134 0.2× 18 0.0× 303 0.6× 553 1.7× 78 1.2k
Diana M. Cittelly United States 22 661 0.5× 232 0.3× 15 0.0× 1.0k 2.0× 368 1.1× 40 1.9k
Daniel P. Hollern United States 15 660 0.5× 413 0.5× 18 0.0× 566 1.1× 191 0.6× 27 1.3k
Heather J. Dalton United States 16 332 0.3× 251 0.3× 11 0.0× 424 0.8× 107 0.3× 29 990
Justin Bottsford-Miller United States 16 591 0.5× 258 0.3× 5 0.0× 559 1.1× 163 0.5× 42 1.4k

Countries citing papers authored by Janet Maleski

Since Specialization
Citations

This map shows the geographic impact of Janet Maleski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet Maleski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet Maleski more than expected).

Fields of papers citing papers by Janet Maleski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet Maleski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet Maleski. The network helps show where Janet Maleski may publish in the future.

Co-authorship network of co-authors of Janet Maleski

This figure shows the co-authorship network connecting the top 25 collaborators of Janet Maleski. A scholar is included among the top collaborators of Janet Maleski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet Maleski. Janet Maleski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smith, Michael, Robert Newton, Sherry Owens, et al.. (2020). 28 Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies. SHILAP Revista de lepidopterología. A15.2–A16. 12 indexed citations
2.
Long, Georgina V., Reinhard Dummer, Omid Hamid, et al.. (2019). Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. The Lancet Oncology. 20(8). 1083–1097. 703 indexed citations breakdown →
3.
Zhang, Yan, Kevin Bowman, Janet Maleski, Sharon Diamond, & Swamy Yeleswaram. (2019). Short Communication: Effects of Epacadostat on Brain Extracellular Fluid Concentrations of Serotonin—an Intracerebral Microdialysis Study in Sprague-Dawley Rats. Drug Metabolism and Disposition. 47(7). 710–714.
4.
Gibney, Geoffrey T., Omid Hamid, Jose Lutzky, et al.. (2019). Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. Journal for ImmunoTherapy of Cancer. 7(1). 65 indexed citations
5.
Long, Georgina V., Reinhard Dummer, Omid Hamid, et al.. (2018). Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.. Journal of Clinical Oncology. 36(15_suppl). 108–108. 102 indexed citations
6.
Mitchell, Tara C., Omid Hamid, David C. Smith, et al.. (2018). Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). Journal of Clinical Oncology. 36(32). 3223–3230. 305 indexed citations
7.
Hamid, Omid, Thomas F. Gajewski, Arthur E. Frankel, et al.. (2017). Epacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037. Annals of Oncology. 28. v428–v429. 36 indexed citations
8.
9.
Smith, David C., Thomas F. Gajewski, Omid Hamid, et al.. (2017). Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.. Journal of Clinical Oncology. 35(15_suppl). 4503–4503. 52 indexed citations
10.
Spira, Alexander I., Omid Hamid, Todd M. Bauer, et al.. (2017). Efficacy/safety of epacadostat plus pembrolizumab in triple-negative breast cancer and ovarian cancer: Phase I/II ECHO-202 study.. Journal of Clinical Oncology. 35(15_suppl). 1103–1103. 36 indexed citations
11.
Beatty, Gregory L., Peter J. O’Dwyer, Jason Clark, et al.. (2017). First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 23(13). 3269–3276. 240 indexed citations
12.
Shi, Jack, Kevin Bowman, Xuejun Chen, et al.. (2016). Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies. The Journal of Clinical Pharmacology. 57(6). 720–729. 13 indexed citations
13.
Gangadhar, Tara C., Omid Hamid, David C. Smith, et al.. (2016). Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037. Annals of Oncology. 27. vi380–vi380. 47 indexed citations
14.
Gibney, Geoffrey T., Omid Hamid, Jose Lutzky, et al.. (2015). 511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma. European Journal of Cancer. 51. S106–S107. 28 indexed citations
15.
Gangadhar, Tara C., Omid Hamid, David C. Smith, et al.. (2015). Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. Journal for ImmunoTherapy of Cancer. 3(S2). 58 indexed citations
16.
Gibney, Geoffrey T., Omid Hamid, Tara C. Gangadhar, et al.. (2014). Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma.. Journal of Clinical Oncology. 32(15_suppl). 3010–3010. 45 indexed citations
17.
Beatty, Gregory L., Peter J. O’Dwyer, Jason Clark, et al.. (2013). Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.. Journal of Clinical Oncology. 31(15_suppl). 3025–3025. 34 indexed citations
18.
MacVicar, Gary R., et al.. (2009). An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 27(15_suppl). 5062–5062. 11 indexed citations
19.
Poiesz, Bernard J., James A. Reeves, William McNulty, et al.. (2009). Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel refractory prostate cancer. Journal of Clinical Oncology. 27(15_suppl). 5145–5145. 7 indexed citations
20.
Blackwell, Kimberly, et al.. (2004). A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Journal of Clinical Oncology. 22(14_suppl). 3006–3006. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by De-Sheng Weng Breakdown of academic impact, for papers by Gengjie Yang Breakdown of academic impact, for papers by Agnes Witkiewicz Breakdown of academic impact, for papers by Jamaal Rehman Breakdown of academic impact, for papers by Dorothee Gramatzki Breakdown of academic impact, for papers by Hua Zhong Breakdown of academic impact, for papers by Diana M. Cittelly Breakdown of academic impact, for papers by Daniel P. Hollern Breakdown of academic impact, for papers by Heather J. Dalton Breakdown of academic impact, for papers by Justin Bottsford-Miller
Rankless by CCL
2026